Does an everolimus-eluting bioresorbable vascular scaffold prevent target-lesion failure at 1 year in patients with noncomplex obstructive coronary artery disease compared to an everolimus-eluting cobalt-chromium stent?
Everolimus-eluting bioresorbable vascular scaffolds demonstrated noninferiority to everolimus-eluting cobalt-chromium stents for target-lesion failure at 1 year in noncomplex obstructive CAD.
In this large-scale, randomized trial, treatment of noncomplex obstructive coronary artery disease with an everolimus-eluting bioresorbable vascular scaffold, as compared with an everolimus-eluting cobalt-chromium stent, was within the prespecified margin for noninferiority with respect to target-lesion failure at 1 year. (Funded by Abbott Vascular; ABSORB III ClinicalTrials.gov number, NCT01751906.).
“As a clinician, I really want to see that long-term data before switching my practice to BVS because we have been burnt in the past before, switching to newer devices without longer-term data.”
Ellis et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: